<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02292719</url>
  </required_header>
  <id_info>
    <org_study_id>M14-567</org_study_id>
    <secondary_id>2014-003147-35</secondary_id>
    <nct_id>NCT02292719</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety and Efficacy of Ombitasvir/ABT-450/Ritonavir With Sofosbuvir With and Without Ribavirin in Adults With Chronic Hepatitis C Virus Infection</brief_title>
  <acronym>Quartz II/III</acronym>
  <official_title>A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of the Co-Administration of Ombitasvir/ABT-450/Ritonavir (Ombitasvir/ABT-450/r) With Sofosbuvir (SOF) With or Without Ribavirin (RBV) in Subjects With Genotype 2 Chronic Hepatitis C Virus (HCV) Infection or Genotype 3 HCV Infection With or Without Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and efficacy of ombitasvir/ABT-450/r with
      sofosbuvir with or without ribavirin in adults with Genotype 2 Chronic Hepatitis C Virus
      (HCV)infection or Genotype 3 HCV infection With or Without Cirrhosis.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 19, 2014</start_date>
  <completion_date type="Actual">July 14, 2017</completion_date>
  <primary_completion_date type="Actual">July 14, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with sustained virologic response 12 weeks (SVR12) post-treatment</measure>
    <time_frame>12 weeks after the last dose of active drug</time_frame>
    <description>Hepatitis C virus ribonucleic acid less than the lower limit of quantification.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with on-treatment virologic failure</measure>
    <time_frame>Up to Week 12</time_frame>
    <description>Hepatitis C virus ribonucleic acid greater than or equal to the lower limit of quantification after hepatitis C virus ribonucleic acid less than lower limit of quantification or confirmed 1 log10 IU/mL increase from nadir in hepatitis C virus ribonucleic acid at any time point during treatment, or failure to suppress during treatment with at least 6 weeks of treatment (defined as active study drug duration â‰¥ 36 days) of treatment for 12-week and 8-week treatment or at least 26 days of treatment for 6-week treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of participants with virologic relapse after treatment</measure>
    <time_frame>Up to 12 weeks after the last actual dose of active study drug</time_frame>
    <description>Hepatitis C Virus (HCV) ribonucleic acid (RNA) confirmed greater than or equal to the lower limit of quantification between the end of treatment and 12 weeks post treatment among subjects completing treatment and with HCV RNA less than the lower limit of quantification at the end of treatment.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Chronic Hepatitis C Virus Infection</condition>
  <arm_group>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r with sofosbuvir (SOF) once daily and ribavirin twice daily for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ombitasvir/ABT-450/r and sofosbuvir (SOF) once daily for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/ABT-450/r</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm A:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm F:Ombitasvir/ABT-450/r and sofosbuvir (SOF)</arm_group_label>
    <other_name>Sovaldi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ribavirin (RBV)</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Arm B;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm C:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm D:Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
    <arm_group_label>Arm E;Ombitasvir/ABT-450/r with sofosbuvir (SOF) and ribavirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Chronic HCV infection prior to study enrollment.

          2. Screening laboratory results from the central clinical laboratory indicating HCV
             genotype 2 or 3 infection only (no mixed genotype).

          3. Absence OR presence of cirrhosis.

          4. If cirrhotic, need to have compensated cirrhosis and absence of hepatocellular
             carcinoma (HCC)

        Exclusion Criteria:

          1. Positive screen for hepatitis B surface antigen or anti-human immunodeficiency virus
             antibody

          2. Recent (within 6 months prior to study drug administration) history of drug or alcohol
             abuse.

          3. Current enrollment in another clinical study, previous enrolment in this study, or
             previous use of any investigational or commercially available anti-HCV therapy (other
             than interferon, pegIFN, RBV, and or SOF) including previous exposure to telaprevir,
             boceprevir, ABT-450, or ombitasvir (ABT-267).

          4. Subjects without cirrhosis: Any current or past clinical evidence of cirrhosis.

          5. Abnormal lab tests.

          6. Females who are pregnant or plan to become pregnant or breastfeeding, or males whose
             partners are pregnant or planning to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mariem Charafeddine, MD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Adelaide Hospital /ID# 132014</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Alberta /ID# 132436</name>
      <address>
        <city>Edmonton</city>
        <zip>T6G 2B7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Auckland Clinical Studies Limited /ID# 132013</name>
      <address>
        <city>Grafton</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Royal London Hospital /ID# 132011</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King's College Hospital /ID# 132012</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 13, 2014</study_first_submitted>
  <study_first_submitted_qc>November 13, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 17, 2014</study_first_posted>
  <last_update_submitted>July 18, 2017</last_update_submitted>
  <last_update_submitted_qc>July 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Hepatitis C Virus</keyword>
  <keyword>Genotype 2</keyword>
  <keyword>Chronic Hepatitis C</keyword>
  <keyword>Genotype 3</keyword>
  <keyword>Non-cirrhotic</keyword>
  <keyword>Cirrhotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ribavirin</mesh_term>
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

